TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01715584

Intervention type: OTHER
Group type: OTHER
Intervention: Sevoflurane/oxygen/air/nitrous oxide
Description: Patients in each arm will be randomized to receive either: 50 per cent oxygen, air, and sevoflurane or 50% nitrous oxide, oxygen and sevoflurane. They will then cross over to the other gas mixture. The depth of each the anesthetic will be varied from 0.8 MAC (minimum alveolar concentration) to 1.6 MAC in 0.2 MAC steps. Hemodyamic variables will be measured at each anesthetic concentration (average of five measurements). Time will be allowed for anesthetic agent equilibration. Paralysis and analgesia using rocuronium and fentanyl will be provided to ensure patients do not move at low (less than 1.0 MAC. It is estimated the time for the cross over experiment will be approximately six hours.

Intervention type: OTHER
Group type: OTHER
Intervention: Sevoflurane/oxygen/air/nitrous oxide
Description: Patients in each arm will be randomized to receive either: 50 per cent oxygen, air, and sevoflurane or 50% nitrous oxide, oxygen and sevoflurane. They will then cross over to the other gas mixture. The depth of each the anesthetic will be varied from 0.8 MAC (minimum alveolar concentration) to 1.6 MAC in 0.2 MAC steps. Hemodyamic variables will be measured at each anesthetic concentration (average of five measurements). Time will be allowed for anesthetic agent equilibration. Paralysis and analgesia using rocuronium and fentanyl will be provided to ensure patients do not move at low (less than 1.0 MAC. It is estimated the time for the cross over experiment will be approximately six hours.

Intervention type: OTHER
Group type: OTHER
Intervention: Sevoflurane/oxygen/air/nitrous oxide
Description: Patients in each arm will be randomized to receive either: 50 per cent oxygen, air, and sevoflurane or 50% nitrous oxide, oxygen and sevoflurane. They will then cross over to the other gas mixture. The depth of each the anesthetic will be varied from 0.8 MAC (minimum alveolar concentration) to 1.6 MAC in 0.2 MAC steps. Hemodyamic variables will be measured at each anesthetic concentration (average of five measurements). Time will be allowed for anesthetic agent equilibration. Paralysis and analgesia using rocuronium and fentanyl will be provided to ensure patients do not move at low (less than 1.0 MAC. It is estimated the time for the cross over experiment will be approximately six hours.
Study: NCT03378063

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: transplantation of mesenchymal stem cell
Description: allogeneic human umbilical cord blood (hUCB)-derived mesenchymal stem cell (MSC) transplantation will be given to preterm infants

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: no transplantation of mesenchymal stem cell
Description: MSC transplantation will be not given to preterm infants
Study: NCT03752645

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transverse Many Channels Laser Instrument
Description: The device consists of a control box and 4 sets of two light-emitting nasal probes. Prior to treatment, each patient put on a pair of black tinted glasses, and had the nasal probes gently placed into both nostrils. A turn-on switch on the control box activated the probe and the timer was set at 15 minutes during which time 36 J of light energy was delivered to each nostril.
Study: NCT01817816

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Botox_A
Study: NCT03692819

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lactobacillus reuteri Oral Drops
Description: Non-surgical periodontal treatment will be performed by means of periodontal debridement in a single session after the therapy will be administered the probiotic (Lactobacillus reuteri oral drops ) twice a day for 21 days.
Study: NCT03453788

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LETSGO app
Description: LETSGO pilot test Group will test LETSGO app and partially nurseled follow-up
Study: NCT04559347

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine (0.5% bolus followed by 0.2% infusion)
Description: Continuous catheter infusion for erector spinae plane block
Study: NCT02263092

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical exercise
Description: The intensity of physical exercise will be determine by the maximum heart rate (max HR) using the formula (220 - age). For the high intensity, the intensity will between 79-95% xx% of maxHR; moderate intensity, 64-76% of maxHR; mild intensity, 57-63% of maxHR. Furthermore, during the physical exercise the heart rate will be continuous evaluate by the POLAR and the rate perceived scale will be register in each 3 minutes by the modified Borg scale

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical exercise
Description: The intensity of physical exercise will be determine by the maximum heart rate (max HR) using the formula (220 - age). For the high intensity, the intensity will between 79-95% xx% of maxHR; moderate intensity, 64-76% of maxHR; mild intensity, 57-63% of maxHR. Furthermore, during the physical exercise the heart rate will be continuous evaluate by the POLAR and the rate perceived scale will be register in each 3 minutes by the modified Borg scale

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical exercise
Description: The intensity of physical exercise will be determine by the maximum heart rate (max HR) using the formula (220 - age). For the high intensity, the intensity will between 79-95% xx% of maxHR; moderate intensity, 64-76% of maxHR; mild intensity, 57-63% of maxHR. Furthermore, during the physical exercise the heart rate will be continuous evaluate by the POLAR and the rate perceived scale will be register in each 3 minutes by the modified Borg scale
Study: NCT02428478

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Desipramine
Description: 200 mg administered 2 hours before normal sleep time

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Desipramine
Description: 200 mg administered 2 hours before normal sleep time

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo-matching desipramine administered 2 hours before normal sleep time

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo-matching desipramine administered 2 hours before normal sleep time
Study: NCT01817816

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Botox_A

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Botox_B

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Botox_B
Study: NCT01515033

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: aerobic exercise training
Description: The continuous exercise training was performed on a treadmill with a 50-minutes duration and intensity at ventilatory anaerobic threshold.~The interval exercise training consisted of 7 sets of 3 minutes at respiratory compensation point and 7 sets of 3 minutes of exercise at moderate intensity corresponding to the ventilatory anaerobic threshold totaling 42 minutes

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: aerobic exercise training
Description: The continuous exercise training was performed on a treadmill with a 50-minutes duration and intensity at ventilatory anaerobic threshold.~The interval exercise training consisted of 7 sets of 3 minutes at respiratory compensation point and 7 sets of 3 minutes of exercise at moderate intensity corresponding to the ventilatory anaerobic threshold totaling 42 minutes
Study: NCT00375102

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acupuncture

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Relaxation Response
Study: NCT02528240

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: EMS

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: EMS

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: + occlusive membrane

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: conebeam CT

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: conebeam CT
Study: NCT00706017

Intervention type: DRUG
Intervention: insulin detemir
Description: Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
Study: NCT00384787

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC-HIVDNA009-00-VP
Description: HIV DNA vaccine containing the HIV genes gag, pol, nef, and env A,B, and C. The HIV DNA vaccine will be given in three doses intramuscularly at study entry and Months 1 and 2

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC-HIVDNA009-00-VP
Description: HIV DNA vaccine containing the HIV genes gag, pol, nef, and env A,B, and C. The HIV DNA vaccine will be given in three doses intramuscularly at study entry and Months 1 and 2

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC-HIVDNA009-00-VP
Description: HIV DNA vaccine containing the HIV genes gag, pol, nef, and env A,B, and C. The HIV DNA vaccine will be given in three doses intramuscularly at study entry and Months 1 and 2

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC-HIVADV014-00-VP
Description: Adenoviral vector HIV booster vaccine containing the HIV genes gag, pol, and env. The adenoviral vector HIV booster vaccine will be administered intramuscularly (Group 1), intradermally (Group 2), or subcutaneously (Group 3) at Month 6

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC-HIVADV014-00-VP
Description: Adenoviral vector HIV booster vaccine containing the HIV genes gag, pol, and env. The adenoviral vector HIV booster vaccine will be administered intramuscularly (Group 1), intradermally (Group 2), or subcutaneously (Group 3) at Month 6

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC-HIVADV014-00-VP
Description: Adenoviral vector HIV booster vaccine containing the HIV genes gag, pol, and env. The adenoviral vector HIV booster vaccine will be administered intramuscularly (Group 1), intradermally (Group 2), or subcutaneously (Group 3) at Month 6
Study: NCT02504229

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: autologous dendritic cells co-cultured with cytokine-induced killer cells

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gimeracil and Oteracil Porassium Capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gimeracil and Oteracil Porassium Capsules

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Study: NCT01501058

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: parent-assisted social skills training program for adolescents with autism spectrum disorder
Description: The subjects will participate in the treatment program weekly for a total of 14 weeks. The final visit will be made at the point three months after the completion of treatment to see mid- and long-term effects.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Delayed intervention
Description: Intervention is provided to Waitlist Control Group after waiting for 14 weeks
Study: NCT03794635

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weekly 45 minute Sessions
Description: The current intervention consists of seven, weekly,45-minute sessions conducted over the telephone using the TAC manual workbook. MSK-approved platforms (such as Webex or Cisco Jabber) can be used for telephone calls in this study. There will be two versions of the intervention used for this study:~1. A culturally tailored version for Latinx participants refined during Phase 1 of this study (available in English and Spanish)~2. A version of the intervention that was not culturally tailored for Latinx patients and caregivers developed in previous work. The two interventions differ in minor content areas. The culturally tailored intervention for Latinx participants and the non-tailored intervention for non-Latinx participants will be used. Interventions will occur weekly with a plus three-week window.~Characteristics of prognostic discussions between patients and caregivers and health providers will be assessed at baseline and post-intervention.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weekly 45 minute Sessions
Description: The current intervention consists of seven, weekly,45-minute sessions conducted over the telephone using the TAC manual workbook. MSK-approved platforms (such as Webex or Cisco Jabber) can be used for telephone calls in this study. There will be two versions of the intervention used for this study:~1. A culturally tailored version for Latinx participants refined during Phase 1 of this study (available in English and Spanish)~2. A version of the intervention that was not culturally tailored for Latinx patients and caregivers developed in previous work. The two interventions differ in minor content areas. The culturally tailored intervention for Latinx participants and the non-tailored intervention for non-Latinx participants will be used. Interventions will occur weekly with a plus three-week window.~Characteristics of prognostic discussions between patients and caregivers and health providers will be assessed at baseline and post-intervention.
Study: NCT01820923

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation (tDCS)
Description: 2 mA of intensity, 20 minutes of stimulation over the left fronto-temporal prefrontal cortex.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Repetitive Transcranial Magnetic Stimulation (rTMS)
Description: Frequency of stimulation: 10Hz. Interstimulus interval: 1 min. Number of stimuli per session: 300. Number of sessions per week: 4 Total number of stimuli: 1.200

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Direct Current Stimulation (SHAM)
Description: The electrodes of stimulation will be applied in the left fronto-temporal prefrontal cortex, but the device will be turned off.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Repetitive Transcranial Magnetic Stimulation (SHAM)
Description: The coil will be applied on the left fronto-temporal prefrontal cortex, but the device will be turned off.
Study: NCT02137993

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: A-prexa
Description: A-prexa 5-20 mg for 6 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zyprexa
Description: Zyprexa 5-20 mg for 6 weeks
Study: NCT02019056

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo /bid P.O

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MG-1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MG-2 : MG1000mg, Placebo /bid P.O

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: metadoxine
Study: NCT01511939

Intervention type: DRUG
Group type: OTHER
Intervention: Pennsaid
Description: Administered 10 drops x 4 until 40 drops applied topically to index knee (and also non-index knee if osteoarthritis pain is present bilaterally) 4 times a day for a 4 week active treatment period.

Intervention type: DRUG
Group type: OTHER
Intervention: Pennsaid
Description: Administered 10 drops x 4 until 40 drops applied topically to index knee (and also non-index knee if osteoarthritis pain is present bilaterally) 4 times a day for a 4 week active treatment period.

Intervention type: DRUG
Group type: OTHER
Intervention: Pennsaid
Description: Administered 10 drops x 4 until 40 drops applied topically to index knee (and also non-index knee if osteoarthritis pain is present bilaterally) 4 times a day for a 4 week active treatment period.
Study: NCT03533283

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glofitamab
Description: Glofitamab will be administered through IV infusion every 3 weeks (Q3W) beginning Cycle 1, Day 1, for up to 17 cycles (Cycle = 21 days). Step-up dosing, in which an initial lower dose will be followed by a higher dose 1 week later, will be considered for the initial treatment phase and for Cycle 9 of the re-treatment phase.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glofitamab
Description: Glofitamab will be administered through IV infusion every 3 weeks (Q3W) beginning Cycle 1, Day 1, for up to 17 cycles (Cycle = 21 days). Step-up dosing, in which an initial lower dose will be followed by a higher dose 1 week later, will be considered for the initial treatment phase and for Cycle 9 of the re-treatment phase.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glofitamab
Description: Glofitamab will be administered through IV infusion every 3 weeks (Q3W) beginning Cycle 1, Day 1, for up to 17 cycles (Cycle = 21 days). Step-up dosing, in which an initial lower dose will be followed by a higher dose 1 week later, will be considered for the initial treatment phase and for Cycle 9 of the re-treatment phase.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab will be administered in combination with Glofitamab through IV infusion Q3W from Cycle 2, Day 1, for up to 16 cycles (Cycle = 21 days).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Obinutuzumab will be administered once, through IV infusion, at a fixed dose 7 days before the first dose of Glofitamab.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Obinutuzumab will be administered once, through IV infusion, at a fixed dose 7 days before the first dose of Glofitamab.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Obinutuzumab will be administered once, through IV infusion, at a fixed dose 7 days before the first dose of Glofitamab.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Tocilizumab will be administered as necessary to treat cytokine release syndrome (CRS).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Tocilizumab will be administered as necessary to treat cytokine release syndrome (CRS).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polatuzumab Vedotin
Description: Polatuzumab vedotin will be administered in combination with Glofitamab (on different days) Q3W from Cycle 1, Day 2, for up to 12 cycles (Cycle = 21 days).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 89Zr-Df-IAB22M2C
Description: Participants will receive 89Zr-Df-IAB22M2C (Cycle 1 only) prior to obinutuzumab pre-treatment and again on Day 10 after dosing with glofitamab, followed by PET/CT.
Study: NCT03524118

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clesrovimab
Description: Single ascending doses of clesrovimab will be administered via IM injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clesrovimab
Description: Single ascending doses of clesrovimab will be administered via IM injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clesrovimab
Description: Single ascending doses of clesrovimab will be administered via IM injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clesrovimab
Description: Single ascending doses of clesrovimab will be administered via IM injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clesrovimab
Description: Single ascending doses of clesrovimab will be administered via IM injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clesrovimab
Description: Single ascending doses of clesrovimab will be administered via IM injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clesrovimab
Description: Single ascending doses of clesrovimab will be administered via IM injection.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (0.9% sodium chloride \[NaCl\]) will be administered via IM injection.
Study: NCT00208026

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pimecrolimus 1% Cream
Description: Open label single arm
Study: NCT02159300

Intervention type: BEHAVIORAL
Intervention: experience brain activity recording
Description: Intervention: experience brain activity recording

Intervention type: BEHAVIORAL
Intervention: experience brain activity recording
Description: Intervention: experience brain activity recording
Study: NCT00874211

Intervention type: PROCEDURE
Intervention: assessment of therapy complications
Description: By dental and medical assessments.
Study: NCT04199325

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotics
Description: Patients will be randomly assigned to the routine treatment + placebo group and probiotics + routine treatment group according to 1:2 ratio.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: uric-acid-lowering drug
Description: Patients will be randomly assigned to the routine treatment + placebo group and probiotics + routine treatment group according to 1:2 ratio.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: uric-acid-lowering drug
Description: Patients will be randomly assigned to the routine treatment + placebo group and probiotics + routine treatment group according to 1:2 ratio.
Study: NCT02800187

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ESWT
Description: Shock waves are defined a sequence of acoustic pulse characterized by a high peak pressure (100 MPa), fast pressure rise (\< 10 ns) and short duration (10 μs).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ESWT
Description: Shock waves are defined a sequence of acoustic pulse characterized by a high peak pressure (100 MPa), fast pressure rise (\< 10 ns) and short duration (10 μs).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ESWT
Description: Shock waves are defined a sequence of acoustic pulse characterized by a high peak pressure (100 MPa), fast pressure rise (\< 10 ns) and short duration (10 μs).
Study: NCT01951001

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prasugrel
Description: For fixed-dose group, patients will receive prasugrel 10 or 5 mg/d for 1 month Irrespective of platelet function test.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prasugrel
Description: For fixed-dose group, patients will receive prasugrel 10 or 5 mg/d for 1 month Irrespective of platelet function test.
Study: NCT01115322

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: No Treatment with UVA and UVB and visible light irradiation
Description: Each subject will be exposed to a blank patch during a single, 24 hour application period. The patch will be removed and that site will be exposed to UVA, UVA/UVB, and visible light (VIS) wavelengths (UV plus VIS).~Patch sites will be evaluated for signs of inflammatory skin responses (eg, erythema and local skin reactions) and superficial effects 1 ±0.25 hour after patch removal, and during follow-up visits at 24 ±1 hours, 48 ±2 hours, and 72 ±2 hours after patch removal.
Study: NCT05379010

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endodontic Microsurgery
Description: Surgical removal of 3 millimeters of the root-end, removal of the apical pathology, Root-end preparation and retrograde filling. The entire procedure is done under magnification.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endodontic Microsurgery
Description: Surgical removal of 3 millimeters of the root-end, removal of the apical pathology, Root-end preparation and retrograde filling. The entire procedure is done under magnification.